IOL Chemicals Secures EDQM Certificate for Antidiabetic API

IOL Chemicals & Pharmaceuticals Limited (IOLCP) has achieved a significant milestone in its pharmaceutical operations. The company announced that it has received a Certificate of Suitability from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its active pharmaceutical ingredient (API) product, Sitagliptin Phosphate Monohydrate.

Key Details of the Certification

Aspect	Information
Certified Product	Sitagliptin Phosphate Monohydrate
Certifying Body	European Directorate for the Quality of Medicines & Health Care (EDQM)
Date of Certification	October 27, 2025
Product Application	Oral antidiabetic medication for controlling high blood sugar levels

Significance of the Certification

The EDQM certification is a crucial development for IOLCP, as it validates the quality and compliance of their API with European standards. This certificate of suitability could potentially open up new market opportunities for the company in the European pharmaceutical sector.

Company Disclosure

In adherence to regulatory requirements, IOLCP promptly communicated this development to the National Stock Exchange of India (NSE) and BSE Limited. The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

About Sitagliptin Phosphate Monohydrate

Sitagliptin Phosphate Monohydrate is an important component in the treatment of diabetes. As an oral antidiabetic medication, it plays a crucial role in helping patients manage their blood sugar levels effectively.

This certification marks a positive step for IOLCP in strengthening its position in the pharmaceutical API market, particularly for diabetes treatment products. It reflects the company's commitment to maintaining high-quality standards in its pharmaceutical manufacturing processes.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.25%	-1.75%	-8.04%	+42.16%	+19.81%	-29.03%

IOL Chemicals & Pharmaceuticals Limited (IOLCP) has taken a significant step towards international expansion by incorporating a wholly-owned subsidiary in the United Kingdom. The new entity, IOL Pharmaxis UK Limited, was established on October 16, 2025, under the Companies Act 2006 of England and Wales.

Key Details of the Subsidiary

Aspect	Details
Name	IOL Pharmaxis UK Limited
Incorporation Date	October 16, 2025
Share Capital	GBP 10,000
Number of Shares	10,000 ordinary shares
Share Value	GBP 1 each
Industry	Pharmaceuticals/Chemicals
Ownership	100% held by IOL Chemicals and Pharmaceuticals Limited
Business Status	Yet to commence operations

Financial and Regulatory Aspects

The establishment of IOL Pharmaxis UK Limited involves a cash consideration for share subscription. IOLCP plans to remit the funds in compliance with the Foreign Exchange Management (Overseas Investment) Regulations, 2022. As a wholly-owned subsidiary, IOL Pharmaxis UK Limited will be classified as a related party to IOLCP.

Strategic Implications

This move by IOLCP signals its intent to strengthen its presence in the global pharmaceuticals and chemicals market. The UK subsidiary could potentially serve as a strategic base for the company's operations in Europe, although specific plans for the new entity's operations have not been disclosed.

Regulatory Compliance

IOLCP has duly informed the National Stock Exchange of India Ltd. and BSE Limited about this development, in line with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided all necessary details as mandated by SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023.

While the incorporation of IOL Pharmaxis UK Limited marks a notable expansion for IOLCP, the subsidiary has yet to commence business operations. The future announcements regarding the operational plans and strategic role of this new UK entity within IOLCP's broader business framework will be of interest to investors and industry observers.